Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 4
2005 3
2006 3
2007 8
2008 6
2009 9
2010 6
2011 2
2012 2
2013 2
2014 4
2015 3
2016 3
2017 4
2018 7
2019 2
2020 15
2021 17
2022 28
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T, Higashi S, Abe Y, Mukai K, Ikawa T, Konishi K, Maeda N, Nakanishi K, Hasegawa S, Wada H, Ohkawa K. Nakabori T, et al. Among authors: ohkawa k. Curr Oncol. 2024 Mar 15;31(3):1543-1555. doi: 10.3390/curroncol31030117. Curr Oncol. 2024. PMID: 38534950 Free PMC article.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: ohkawa k. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study.
Hirao T, Ikezawa K, Morishima T, Daiku K, Seiki Y, Watsuji K, Kawamoto Y, Higashi S, Urabe M, Kai Y, Takada R, Yamai T, Mukai K, Nakabori T, Uehara H, Miyashiro I, Ohkawa K. Hirao T, et al. Among authors: ohkawa k. BMC Gastroenterol. 2023 Aug 1;23(1):263. doi: 10.1186/s12876-023-02898-x. BMC Gastroenterol. 2023. PMID: 37528334 Free PMC article.
Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry.
Kawamoto Y, Ikezawa K, Tabuchi T, Morishima T, Seiki Y, Watsuji K, Hirao T, Higashi S, Urabe M, Kai Y, Takada R, Yamai T, Mukai K, Nakabori T, Uehara H, Miyashiro I, Ohkawa K. Kawamoto Y, et al. Among authors: ohkawa k. J Cancer Res Clin Oncol. 2023 Nov;149(14):12835-12841. doi: 10.1007/s00432-023-04966-x. Epub 2023 Jul 18. J Cancer Res Clin Oncol. 2023. PMID: 37462770
137 results